Lataa...
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity
Checkpoint blockade immunotherapy is now a first-line treatment option for patients with melanoma. Despite achieving objective responses in about half of patients, the exact immune mechanisms elicited and those required for therapeutic success have not been clearly identified. Insight into these mec...
Tallennettuna:
| Julkaisussa: | Cancer Immunol Immunother |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6939620/ https://ncbi.nlm.nih.gov/pubmed/31104075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02346-4 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|